Belgium· BE-AMP-SAM566666-00
Reblozyl 75 mg
A luspatercept product containing luspatercept, registered in Belgium by Bristol-Myers Squibb Pharma. The same ATC class is registered in 14 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Luspatercept is registered in 14 of 19 countries.
Countries holding a registration under ATC B03XA06 (luspatercept), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 10 of them publish a price we can compare per daily dose
Luspatercept · ATC B03XA06
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Luspatercept
- Manufacturer
- Bristol-Myers Squibb Pharma
- Country
- Belgium (BE)
- ATC code
- B03XA06
- ATC class
- Luspatercept
- Defined daily dose
- 3.33 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 4
- be_apb7731268
- be_apb7747058
- be_apb4969267
- be_apb4225652
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Luspatercept in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandReblozyl 75 mg, Pulver zur Herstellung einer InjektionslösungBristol-Myers Squibb SA
- CzechiaREBLOZYLBristol-Myers Squibb Pharma EEIG, Dublin
- SpainREBLOZYL 75 MG POLVO PARA SOLUCION INYECTABLEBristol-Myers Squibb Pharma Eeig
- IcelandReblozylBristol-Myers Squibb Pharma EEIG*
- NorwayReblozylBristol-Myers Squibb Pharma EEIG (1)
- PolandReblozylBristol-Myers Squibb Pharma EEIG
- SwedenReblozyl 75 mg Pulver till injektionsvätska, lösningBristol-Myers Squibb Pharma EEIG
- United StatesReblozylCelgene Corporation
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Reblozyl
- Liechtenstein · Reblozyl
- Norway · Reblozyl
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/de275bf0-7ce5-4e08-97cc-347654157da3 GET /v1/drugs/de275bf0-7ce5-4e08-97cc-347654157da3?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Powder for solution for injection",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Reblozyl 75 mg",
"name_fr": "Reblozyl 75 mg",
"name_nl": "Reblozyl 75 mg",
"amp_code": "SAM566666-00",
"strengths": [
"75.0000"
],
"pack_count": 2,
"substances": [
"Luspatercept",
"Sodium Hydroxide",
"Sucrose",
"Polysorbate 80"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Luspatercept",
"authorisation_numbers": [
"EU/1/20/1452/002"
]
}See everything about luspatercept.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.